title: CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway.
authors.affiliation: Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR, USA.
authors.forename: R C
authors.initials: RC
authors.lastname: Prins
authors.forename: R T
authors.initials: RT
authors.lastname: Burke
authors.forename: J W
authors.initials: JW
authors.lastname: Tyner
authors.forename: B J
authors.initials: BJ
authors.lastname: Druker
authors.forename: M M
authors.initials: MM
authors.lastname: Loriaux
authors.forename: S E
authors.initials: SE
authors.lastname: Spurgeon
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives; D000970:Antineoplastic Agents / Q000494:pharmacology; D047390:Casein Kinase II / Q000037:antagonists & inhibitors* / Q000378:metabolism; D004357:Drug Synergism; D019337:Hematologic Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D007074:Immunoglobulin G / Q000494:pharmacology; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000378:metabolism; D009287:Naphthyridines / Q000494:pharmacology*; D010619:Phenazines; D010880:Piperidines; D011379:Prognosis; D011687:Purines / Q000494:pharmacology; D011720:Pyrazoles / Q000494:pharmacology; D011743:Pyrimidines / Q000494:pharmacology; D052999:Quinazolinones / Q000494:pharmacology; D011947:Receptors, Antigen, B-Cell / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects*; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000494:pharmacology
chemical_list: D000970:Antineoplastic Agents; D007074:Immunoglobulin G; D009287:Naphthyridines; D010619:Phenazines; D010880:Piperidines; D011687:Purines; D011720:Pyrazoles; D011743:Pyrimidines; D052999:Quinazolinones; D011947:Receptors, Antigen, B-Cell; C551803:ibrutinib; C555142:silmitasertib; D047390:Casein Kinase II; D014740:Vidarabine; D000225:Adenine; C024352:fludarabine; C552946:idelalisib